NKAPL (NFKB activating protein-like) is a testis-specific transcriptional regulator that functions primarily in meiotic progression and spermatogenesis. Its mechanism involves facilitating RNA polymerase II pause-release by recognizing and stabilizing R-loop structures at GAA-rich loci, thereby coordinating transcription elongation with initiation through the SOX30/HDAC3 complex 1. This process is critical for the meiotic-to-postmeiotic transcriptome switch, enabling haploid gene expression during meiotic exit 1. Genetically, NKAPL variants associate with male infertility; both frameshift mutations and common SNPs (rs1635) in NKAPL cause azoospermia in humans 1. Beyond reproductive function, NKAPL shows disease relevance across multiple conditions: genetic variants associate with schizophrenia susceptibility in Han Chinese populations 23, and NKAPL is consistently downregulated across diverse cancer types 4. Epigenetic dysregulation of NKAPL—specifically promoter hypermethylation—correlates with acquired platinum resistance in ovarian cancer and serves as a prognostic marker in triple-negative breast cancer 56. Clinically, NKAPL represents a potential biomarker for chemotherapy resistance and psychiatric disease risk, though functional relationships in non-reproductive tissues require further investigation.